Le Lézard
Classified in: Science and technology
Subject: ACC

Asetek A/S - Outcome of Extraordinary General Meeting


AALBORG, Denmark, Dec. 5, 2023 /PRNewswire/ -- Today an extraordinary general meeting of Asetek A/S (the "Company") was held at 10:00 AM CET at the Company's headquarter, Assensvej 2, DK-9220 Aalborg East, Denmark.

All proposals as stated in the notice were adopted.

Further information is available at www.asetek.com.

For further information, please contact:
Peter Dam Madsen, Chief Financial Officer
Mobile: +45 2080 7200
e-mail: [email protected]

The following files are available for download:

https://mb.cision.com/Main/6758/3888430/2474922.pdf

Release

 

SOURCE Asetek


These press releases may also interest you

at 01:35
KKR Invests in Healthcare Revenue Solutions Provider Infinx
KKR, a leading global investment firm, and Infinx Services Private Limited ("Infinx" or the 'Company'), an AI-driven healthcare revenue cycle solutions provider, today announced the acquisition of a significant minority stake in Infinx by a...

at 01:18
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting
. Hansa Biopharma, "Hansa" (STOCKHOLM: HNSA), today announced data featuring imlifidase will be presented at the American Transplant Congress (ATC), the joint annual meeting of the American Society of Transplant Surgeons (ASTS) and the American...

at 01:05
Elliptic Labs Shipping AI Virtual Smart Sensor on vivo's Y200 Smartphone
Elliptic Labs (OSE: ELABS), a global AI software company and the world leader in AI Virtual Smart Sensorstm currently deployed in over 500 million devices, is announcing the deployment of its AI Virtual Proximity Sensortm INNER BEAUTY® on vivo's...

at 01:05
FDA Grants Breakthrough Therapy Designation to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with...

at 01:05
Innate Pharma: Clarification Regarding SAR443579 Designation
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by...

at 01:00
Huasun Energy Wins 1GW HJT Solar Module Procurement Bid from China Datang
Huasun Energy has successfully secured a significant bid for China Datang Corporation Ltd.'s (China Datang) 2024-2025 centralized procurement of 1GW n-type heterojunction (HJT) photovoltaic (PV) modules. This achievement highlights Huasun's advanced...

More news about Science and technology...


News published on and distributed by: